试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-25
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
编号:NCT02546869登记状态:入组前撤回企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Lebrikizumab、Prefilled Syringes
登记的停止原因(原文):The study was withdrawn due to an internal decision.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-25
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
编号:NCT03023904登记状态:入组前撤回企业 / 申办者:Vanderbilt-Ingram Cancer Center
药物 / 成分:Nivolumab、Laboratory Biomarker Analysis
登记的停止原因(原文):Research cancelled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-20
Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients
编号:NCT01566422登记状态:入组前撤回企业 / 申办者:Vanderbilt University Medical Center
药物 / 成分:Vancomycin powder
登记的停止原因(原文):unable to enroll any participants
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-20
Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma
编号:NCT02955524登记状态:入组前撤回企业 / 申办者:University of Miami
药物 / 成分:Tetracaine 0.5%、Lidocaine hydrochloride ophthalmic gel 3.5%
登记的停止原因(原文):I discontinued this study because I transferred to another institution.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-19
Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study
编号:NCT02098785登记状态:入组前撤回企业 / 申办者:University of Birmingham
药物 / 成分:Caffeine citrate
登记的停止原因(原文):Local resource issue - never actually started post ethics approval.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-19
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
编号:NCT02680951登记状态:入组前撤回企业 / 申办者:Emory University
药物 / 成分:Dasatinib、Fludarabine、Cytarabine、Idarubicin
登记的停止原因(原文):Withdrawn due to lack of participants.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-18
Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes
编号:NCT01265017登记状态:入组前撤回企业 / 申办者:Sansum Diabetes Research Institute
药物 / 成分:Estradiol, medroxyprogesterone, hydrocortisone, GH、Matching placebo
登记的停止原因(原文):Insufficient funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-18
Mesenchymal Stromal Cells for Ischemic Stroke
编号:NCT01922908登记状态:入组前撤回企业 / 申办者:Sean Savitz
药物 / 成分:MSC Infusion、Placebo Comparator
登记的停止原因(原文):Plan to change the trial design
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-18
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
编号:NCT02989129登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Questionnaires、Quercetin
登记的停止原因(原文):FDA IND Approval
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-17
Improving Fibrosis Outcomes With Metformin
编号:NCT02306070登记状态:入组前撤回企业 / 申办者:Ottawa Hospital Research Institute
药物 / 成分:Metformin、No metformin treatment
登记的停止原因(原文):insufficient funding
查看官方原始记录 ↗